Castle Rock firm Venaxis acquires Boulder-based BiOptix Diagnostics

BOULDER — Castle Rock biotechnology firm Venaxis Inc. (Nasdaq: APPY) has acquired Boulder-based BiOptix Diagnostics Inc. in an all-stock transaction worth roughly $2.6 million, with plans for the combined operation to be located in Boulder.

In a regulatory filing made late Tuesday, Venaxis officials said the company had acquired all of the outstanding Series 1 preferred stock of BiOptix, accounting for more than 98 percent of the outstanding voting stock of BiOptix. In exchange, the selling BiOptix shareholders received an aggregate 627,010 shares of Venaxis, representing about 14 percent of the Venaxis outstanding common stock following the transaction.

The deal closed Monday,…